Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

• Main Authors: Ai-Min Hui (Author), Jingxin Li (Author), Li Zhu (Author), Rong Tang (Author), Huayue Ye (Author), Mei Lin (Author), Lei Ge (Author), Xiyuan Wang (Author), Fuzhong Peng (Author), Zhenggang Wu (Author), Xiling Guo (Author), Yunfeng Shi (Author), Hongxing Pan (Author), Jiahong Zhu (Author), Zhizhou Song (Author), Jingjun Qiu (Author), Wei Wang (Author), Jianfei Zheng (Author), Orkun Ozhelvaci (Author), Svetlana Shpyro (Author), Meghan Bushway (Author), Evelyna Derhovanessian (Author), Marie-Cristine Kühnle (Author), Ulrich Luxemburger (Author), Alexander Muik (Author), Yoana Shishkova (Author), Zakaria Khondker (Author), Simin Hu (Author), Eleni Lagkadinou (Author), Uğur Şahin (Author), Özlem Türeci (Author), Fengcai Zhu (Author)
• Format: Book
• Published: Elsevier, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. Methods: This phase 2, randomised, double-blind, placebo-controlled trial included healthy or medically stable individuals aged 18-85 y...